Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Ovarian Neoplasms 37Carcinoma, Non-Small-Cell Lung 23Uterine Cervical Neoplasms 22Melanoma 22Carcinoma, Renal Cell 18Endometrial Neoplasms 16Colorectal Neoplasms 15Carcinoma, Transitional Cell 15Triple Negative Breast Neoplasms 13Stomach Neoplasms 13Fallopian Tube Neoplasms 12Squamous Cell Carcinoma of Head and Neck 10Carcinoma, Hepatocellular 10Pancreatic Neoplasms 9Breast Neoplasms 9Head and Neck Neoplasms 8Carcinoma, Ovarian Epithelial 8Carcinoma, Merkel Cell 8Small Cell Lung Carcinoma 7Prostatic Neoplasms 7Neoplasms 7Neoplasm Metastasis 7Lung Neoplasms 6Esophageal Neoplasms 6Cholangiocarcinoma 6Urinary Bladder Neoplasms 5Mesothelioma 5Lymphoma 4Carcinosarcoma 4Vulvar Neoplasms 3

Interventions

trifluridine tipiracil drug combination 1Oxaliplatin 1Nivolumab 1Leucovorin 1Fluorouracil 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenomatous Polyposis Coli × Nivolumab × Gynecologic × Clear all
NCT05919264 2026-05-28

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Parabilis Medicines, Inc.

Phase 1/2 Recruiting
595 enrolled
CNSGastrointestinalGenitourinaryGynecologicSarcoma

Craniopharyngioma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Adenomatous Polyposis Coli, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡